90% of drug candidates fail, delaying help for people in need. We’re on a mission to change that.

Better target discovery starts with the right systems biology approach, enabled by an integrated stack of founder population multi-omics, real-world patient data, and well-characterized phenotypes.

The ability to create powered discovery cohorts for common and rare disease indications is not available everywhere, but it is in Newfoundland and Labrador.

founder effect: less biological variation enables more efficient identification of low frequency, high impact variants

complete health records: highly consistent phenotypic stratification to uncover new links between variants and disease

Our platform is where systems biology and data-driven computation meet to identify the true signals of disease.